LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Puma Biotechnology Inc

Suletud

SektorTervishoid

6.01 -3.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.93

Max

6.2

Põhinäitajad

By Trading Economics

Sissetulek

3M

12M

Müük

21M

76M

P/E

Sektori keskmine

8.676

66.845

Kasumimarginaal

15.633

Töötajad

172

EBITDA

13M

27M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-19.74% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-35M

324M

Eelmine avamishind

9.07

Eelmine sulgemishind

6.01

Uudiste sentiment

By Acuity

50%

50%

154 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 19:32 UTC

Omandamised, ülevõtmised, äriostud

Diana Shipping Increases Offer to Acquire Genco -- Update

6. märts 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6. märts 2026, 22:26 UTC

Uudisväärsed sündmused

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6. märts 2026, 22:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6. märts 2026, 21:50 UTC

Market Talk
Uudisväärsed sündmused

Financial Services Roundup: Market Talk

6. märts 2026, 21:37 UTC

Tulu

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6. märts 2026, 21:25 UTC

Uudisväärsed sündmused

How The Iran War Impacts Ukraine. -- Barrons.com

6. märts 2026, 21:17 UTC

Tulu

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6. märts 2026, 20:50 UTC

Tulu

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6. märts 2026, 20:46 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6. märts 2026, 20:31 UTC

Uudisväärsed sündmused

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6. märts 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6. märts 2026, 20:12 UTC

Market Talk
Uudisväärsed sündmused

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6. märts 2026, 19:10 UTC

Market Talk
Uudisväärsed sündmused

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6. märts 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6. märts 2026, 18:44 UTC

Market Talk
Uudisväärsed sündmused

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6. märts 2026, 18:08 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6. märts 2026, 17:46 UTC

Uudisväärsed sündmused

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6. märts 2026, 17:40 UTC

Market Talk
Tulu

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6. märts 2026, 17:40 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 17:32 UTC

Market Talk
Uudisväärsed sündmused

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6. märts 2026, 17:28 UTC

Market Talk
Uudisväärsed sündmused

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6. märts 2026, 17:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

6. märts 2026, 17:20 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

6. märts 2026, 17:20 UTC

Omandamised, ülevõtmised, äriostud

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-19.74% langus

12 kuu keskmine prognoos

Keskmine 5 USD  -19.74%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

154 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat